Trial Profile
Effect of Repaglinide Versus Metformin Treatment in Combination With Insulin Biasp30 (Novologmix 70/30) Predinner on Glycemic and Non-Glycemic Cardiovascular Risk-Factors in Non-Obese Patients With Type-2-Diabetes With Unsatisfactory Glycaemic Control With Oral Hypoglycaemic Agents
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Repaglinide (Primary) ; Insulin aspart/insulin protamine aspart; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 11 Nov 2009 Results published in BMJ.
- 07 Dec 2008 Status changed from active, no longer recruiting to completed, as reported on ClinicalTrials.gov.
- 03 Dec 2005 New trial record.